

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1681)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, 31 MAY 2019

The Board is pleased to announce that, at the EGM held on Friday, 31 May 2019, all the resolutions proposed were passed by the Shareholders of the Company.

Reference is made to the circular of Consun Pharmaceutical Group Limited (the “**Company**”) dated 16 May 2019 (the “**Circular**”) and the notice of the extraordinary general meeting (the “**EGM**”) dated 16 May 2019. Terms used in this announcement shall have the same meaning as those defined in the Circular unless the context requires otherwise.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, at the EGM held on Friday, 31 May 2019, all proposed resolutions as set out in the notice of EGM dated 16 May 2019 were passed by way of poll.

As at the date of the EGM, the total number of issued Shares of the Company was 872,058,780 Shares. As set out in the Circular, Mr. AN Yubao, Ms. LI Qian and their associates and all core connected persons of the Company, holding an aggregate of 453,143,078 Shares of the Company (representing approximately 51.96% of the total number of issued Shares of the Company) were entitled to attend the EGM and should abstain from voting in favour on the resolutions numbered 1 and 2 as set out in the notice of EGM dated 16 May 2019. Accordingly, as at the date of the EGM, there was a total of 418,915,702 Shares, representing approximately 48.04% of the total number of issued Shares of the Company, entitling the Independent Shareholders to attend and vote on the resolutions numbered 1 and 2 at the EGM.

Save as disclosed above, there were no restrictions on any Shareholders of the Company to attend and vote on the resolutions at the EGM.

The poll results in respect of the resolutions are as follows:

Ordinary resolutions		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
1.	To approve the grant of Share Options to Mr. AN Yubao under the Share Option Scheme of the Company.	142,779,659 (55.26%)	115,609,655 (44.74%)
2.	To approve the grant of Share Options to Ms. LI Qian under the Share Option Scheme of the Company.	135,645,569 (52.50%)	122,743,745 (47.50%)
3.	To approve the refreshment of the 10% existing Scheme Mandate Limit under the Share Option Scheme.	309,809,089 (71.62%)	122,743,745 (28.38%)

As more than 50% of the votes were cast in favour of the each of the above resolutions, all such resolutions were duly passed by the Shareholders of the Company as ordinary resolutions by way of poll. The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

By Order of the Board
Consun Pharmaceutical Group Limited
An Yubao
Chairman

Hong Kong, 31 May 2019

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian, Professor ZHU Quan and Mr. TANG Ning as executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive Directors.